Page 89 - 《中国药房》2022年18期

CA Cancer J Clin，2021，71（3）：209-249. therapy as first-line therapy for advanced or metastatic
[ 2 ] LI S B，CHEN H，MAN J Y，et al. Changing trends in the esophageal squamous cell carcinoma in China[J]. Front
disease burden of esophageal cancer in China from 1990 Oncol，2021，11：790373.
to 2017 and its predicted level in 25 years[J]. Cancer Med， [14] SHI G H，PARK S H，REN H Y，et al. Cost analysis for
2021，10（5）：1889-1899. different sequential treatment regimens for metastatic
[ 3 ] ARNOLD M，FERLAY J，VAN BERGE HENEGOUWEN renal cell carcinoma in China[J]. J Med Econ，2018，21
M I，et al. Global burden of oesophageal and gastric can‐ （12）：1150-1158.
cer by histology and subsite in 2018[J]. Gut，2020，69（9）： [15] YANG F，FU Y，KUMAR A，et al. Cost-effectiveness
1564-1571. analysis of camrelizumab in the second-line treatment for
[ 4 ] MURO K，LORDICK F，TSUSHIMA T，et al. Pan-Asian advanced or metastatic esophageal squamous cell carci‐
adapted ESMO clinical practice guidelines for the manage‐ noma in China[J]. Ann Transl Med，2021，9（15）：1226.
ment of patients with metastatic oesophageal cancer：a [16] ZHAN M，XU T，ZHENG H R，et al. Cost-effectiveness
JSMO-ESMO initiative endorsed by CSCO，KSMO， analysis of pembrolizumab in patients with advanced
MOS，SSO and TOS[J]. Ann Oncol，2019，30（1）：34-43. esophageal cancer based on the KEYNOTE-181 study[J].
[ 5 ] ASSERSOHN L，BROWN G，CUNNINGHAM D，et al. Front Public Health，2022，10：790225.
Phase Ⅱ study of irinotecan and 5-fluorouracil/leucovorin [17] WU B，DONG B J，XU Y J，et al. Economic evaluation of
in patients with primary refractory or relapsed advanced first-line treatments for metastatic renal cell carcinoma：a
oesophageal and gastric carcinoma[J]. Ann Oncol，2004， cost-effectiveness analysis in a health resource-limited set‐
15（1）：64-69. ting[J]. PLoS One，2012，7（3）：e32530.
[ 6 ] FORD H E，MARSHALL A，BRIDGEWATER J A，et al. [18] WILKE H，MURO K，VAN CUTSEM E，et al. Ramuci‐
Docetaxel versus active symptom control for refractory rumab plus paclitaxel versus placebo plus paclitaxel in
oesophagogastric adenocarcinoma（COUGAR-02）：an patients with previously treated advanced gastric or gas-
open-label，phase 3 randomised controlled trial[J]. Lancet trooesophageal junction adenocarcinoma（RAINBOW）：a
Oncol，2014，15（1）：78-86. double-blind，randomised phase 3 trial[J]. Lancet Oncol，
[ 7 ] HUANG J，XU J M，CHEN Y，et al. Camrelizumab ver‐ 2014，15（11）：1224-1235.
sus investigator’s choice of chemotherapy as second-line [19] AL-BATRAN S E，VAN CUTSEM E，OH S C，et al.
therapy for advanced or metastatic oesophageal squamous Quality-of-life and performance status results from the
cell carcinoma（ESCORT）：a multicentre，randomised， phase Ⅲ RAINBOW study of ramucirumab plus pacli‐
open-label，phase 3 study[J]. Lancet Oncol，2020，21（6）： taxel versus placebo plus paclitaxel in patients with pre-
832-842. viously treated gastric or gastroesophageal junction adeno‐
[ 8 ] SHEN L，KATO K，KIM S B，et al. Tislelizumab versus carcinoma[J]. Ann Oncol，2016，27（4）：673-679.
chemotherapy as second-line treatment for advanced or [20] LIL Z，LIUX M，HUANGJ，et al. Cost-effectiveness of
metastatic esophageal squamous cell carcinoma camrelizumab versus chemotherapy forthetreatment of ad‐
（RATIONALE-302）：a randomized phase Ⅲ study[J]. J vanced or metastatic esophageal squamous cell carcinoma
Clin Oncol，2022：JCO2101926. [J]. J Gastrointest Oncol，2022，13（1）：40-48.
[ 9 ] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤 [21] LIN Y T，CHEN Y，LIU T X，et al. Cost-effectiveness
学会（CSCO）食管癌诊疗指南：2022[M]. 北京：人民卫生 analysis of camrelizumab immunotherapy versus doce-
出版社，2022：68-91. taxel or irinotecan chemotherapy as second-line therapy
[10] 刘国恩. 中国药物经济学评价指南：2020[M]. 北京：中国 for advanced or metastatic esophageal squamous cell car‐
市场出版社，2020：1-8. cinoma[J]. Cancer Manag Res，2021，13：8219-8230.
[11] BECK J R，PAUKER S G，GOTTLIEB J E，et al. A conve‐ [22] ZHANG P F，XIE D，LI Q. Cost-effectiveness analysis of
nient approximation of life expectancy（the“DEALE”）. nivolumab in the second-line treatment for advanced
Ⅱ. Use in medical decision-making[J]. Am J Med，1982， esophageal squamous cell carcinoma[J]. Future Oncol，
73（6）：889-897. 2020，16（17）：1189-1198.
[12] PURMONEN T，MARTIKAINEN J A，SOINI E J，et al. [23] ZHU Y W，LIU K，DING D，et al. Pembrolizumab plus
Economic evaluation of sunitinib malate in second-line chemotherapy as first-line treatment for advanced esopha‐
treatment of metastatic renal cell carcinoma in Finland[J]. geal cancer：acost-effectiveness analysis[J]. Adv Ther，
Clin Ther，2008，30（2）：382-392. 2022，39（6）：2614-2629.
[13] ZHANG Q L，WU P，HE X C，et al. Cost-effectiveness （收稿日期：2022-05-04 修回日期：2022-08-09）
analysis of camrelizumab vs. placebo added to chemo‐ （编辑：孙 冰）

中国药房 2022年第33卷第18期 China Pharmacy 2022 Vol. 33 No. 18 ·2255·